Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes - Radioactive & Nonradioactive

First-in-human study of a novel somatostatin receptor antagonist 68Ga-NODAGA-LM3 for molecular imaging of paraganglioma patients

AVIRAL SINGH, Jingjing Zhang, Harshad Kulkarni, Thomas Langbein and Richard Baum
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 339;
AVIRAL SINGH
5Zentralklinik Bad Berka GmbH BAD BERKA Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingjing Zhang
4THERANOSTICS Center for Molecular Radiotherapy & Precision Oncology Zentralklinik Bad Berka Bad Berka Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harshad Kulkarni
2Zentralklinik Bad Berka Bad Berka, Thuringia Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas Langbein
3Zentralklinik Bad Berka Erfurt Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Baum
1Zentralklinik Bad Berka Bad Berka Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 60 no. supplement 1 339

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online May 21, 2019.

Copyright & Usage 
© 2019

Author Information

  1. AVIRAL SINGH5,
  2. Jingjing Zhang4,
  3. Harshad Kulkarni2,
  4. Thomas Langbein3 and
  5. Richard Baum1
  1. 1Zentralklinik Bad Berka Bad Berka Germany
  2. 2Zentralklinik Bad Berka Bad Berka, Thuringia Germany
  3. 3Zentralklinik Bad Berka Erfurt Germany
  4. 4THERANOSTICS Center for Molecular Radiotherapy & Precision Oncology Zentralklinik Bad Berka Bad Berka Germany
  5. 5Zentralklinik Bad Berka GmbH BAD BERKA Germany

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: May 2019 to April 2025

AbstractFullPdf
May 2019900
Jun 20194700
Jul 20192600
Aug 20191100
Sep 20193100
Oct 20192800
Nov 20195600
Dec 20192300
Jan 20203100
Feb 20202800
Mar 20203700
Apr 20202200
May 20201800
Jun 20201500
Jul 20201300
Aug 20205100
Sep 20204900
Oct 20204100
Nov 20203500
Dec 20203100
Jan 20211500
Feb 20212700
Mar 20214000
Apr 20213000
May 20212600
Jun 2021900
Jul 20211900
Aug 20214300
Sep 20212200
Oct 20212000
Nov 20217100
Dec 20215500
Jan 20227600
Feb 20222100
Mar 20223100
Apr 20221900
May 20222800
Jun 20221400
Jul 20221500
Aug 2022900
Sep 2022600
Oct 2022700
Nov 2022600
Dec 2022700
Jan 2023800
Feb 2023400
Mar 2023200
Apr 2023400
May 2023600
Jun 2023700
Jul 2023300
Aug 2023300
Sep 2023500
Oct 2023900
Nov 2023400
Dec 2023400
Jan 20241100
Feb 2024700
Mar 2024400
Apr 20241100
May 2024700
Jun 2024300
Jul 2024600
Aug 20241100
Sep 2024400
Oct 20242500
Nov 2024800
Dec 2024700
Jan 2025300
Feb 2025700
Mar 2025500
Apr 2025800
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
First-in-human study of a novel somatostatin receptor antagonist 68Ga-NODAGA-LM3 for molecular imaging of paraganglioma patients
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
First-in-human study of a novel somatostatin receptor antagonist 68Ga-NODAGA-LM3 for molecular imaging of paraganglioma patients
AVIRAL SINGH, Jingjing Zhang, Harshad Kulkarni, Thomas Langbein, Richard Baum
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 339;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
First-in-human study of a novel somatostatin receptor antagonist 68Ga-NODAGA-LM3 for molecular imaging of paraganglioma patients
AVIRAL SINGH, Jingjing Zhang, Harshad Kulkarni, Thomas Langbein, Richard Baum
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 339;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes - Radioactive & Nonradioactive

  • MACROPA highly stable chelator of Radium-223 and functionalization attempts for targeted treatment of cancer
  • Nucleophilic radiofluorination of aryl halides with K18F mediated by well-defined copper complexes
  • SPECT and PET imaging of CD11b-positive immune cells in an orthotopic mouse model of glioma with Zr-89 and Lu-177 labeled Lumi804-anti-CD11b antibody
Show more Molecular Targeting Probes - Radioactive & Nonradioactive

Novel Radiochemistry for Cancer Applications

  • Yttrium-86 PET imaging in rodents to better understand the biodistribution and clearance of gadolinium-based contrast agents used in MRI.
  • Comparison of [18F]DCFPyL Analogues Targeting Prostate-Specific Membrane Antigen (PSMA) in Human Prostate Cancer Xenograft (PCaX) Mouse Models
Show more Novel Radiochemistry for Cancer Applications

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire